ArticleScience (New York, N.Y.)2017
Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.
0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 227 citations in OpenAlex.
- Noncanonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma.The Journal of clinical investigation · 2026Article
- Synergistic role of TFEB/TFE3 and mTORC1 in kidney cystogenesis and tumorigenesis.Cell death and differentiation · 2026Article
- Pathogenic mutations in ATAD3A cause dysregulation of RagC/D-TFEB axis and disrupt lysosomal homeostasis.bioRxiv : the preprint server for biology · 2026Article
- mTORC1-TFEB/TFE3 signaling is associated with bile acid diversification during hepatic metabolic adaptation.Science advances · 2026Article
- RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions.Journal of neuropathology and experimental neurology · 2026Article
- A comprehensive in silico investigation into the deleterious nonsynonymous single nucleotide polymorphisms of the human transcription factor EB (TFEB) gene and their predicted association with cancer.Journal, genetic engineering & biotechnology · 2026Article
- Postoperative management challenges in concurrent endometrioid carcinoma and PEComa a case report.Discover oncology · 2026Article
- Integrated Molecular, Genomic, and Clinical Characterization of Pediatric and Adolescent Translocation Renal Cell Carcinoma: A Report from the Children's Oncology Group.Biomedicines · 2026Article
- Integrative In Silico mRNA-miRNA Profiling of mTOR Pathway Dysregulation in High-Grade Serous Ovarian Carcinoma.Cancers · 2026Article
- TFEB coordinates autophagosome biogenesis and ribophagy during starvation via SQSTM1.Science advances · 2026Article
- FLCN loss is characterized by SQSTM1/p62 accumulation despite functional autophagy flux in Birt-Hogg-Dubé syndrome-associated kidney cancer.Autophagy reports · 2026Article
- Substrate-selective mTORC1 regulation and gene dosage-dependent tissue divergence in Birt-Hogg-Dubé syndrome.Frontiers in oncology · 2026Review
- TFE3 fusion proteins promoted the progression of Xp11.2 translocation renal cell carcinoma through post-translational modification of PDL1 by upregulating CCND1/Cyclin D1.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Lysosomal and mTORC1 signaling dysregulation underpin the pathology of spastic paraplegia type 80.Nature communications · 2025Article
- SFPQ-TFE3 reciprocally regulates mTORC1 and induces lineage plasticity in a mouse model of renal tumorigenesis.Nature communications · 2025Article
- Folliculin Deletion in the Mouse Kidney Results in Cystogenesis of the Loops of Henle via Aberrant TFEB Activation.The American journal of pathology · 2025Article
- Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation.Cell death and differentiation · 2025Article
- Molecular, cellular, biochemical, and rehabilitative insights into exercise interventions for gynecological cancer prevention and survivorship: a narrative review.Journal of ovarian research · 2025Review
- TFE3-rearranged PEComa-like neoplasm of the kidney with carcinoma-like morphology and rapid progression: a case report.World journal of surgical oncology · 2025Article
- Antagonistic roles for MITF and TFE3 in melanoma plasticity.Cell reports · 2025Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 9 institutions in 4 countries.
Chiara Di MaltaTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.ORCID 0000-0001-6524-4354
Diletta SicilianoTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Alessia CalcagniTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Jlenia MonfregolaTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Simona PunziDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.ORCID 0000-0002-8734-6404
Nunzia PastoreDepartment of Molecular and Human Genetics and Neurological Research Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Andrea N EastesDepartment of Anatomy and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-9271-1891
Oliver DavisDepartment of Molecular and Cellular Biology and Paul F. Glenn Center for Aging Research, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-3622-8651
Rossella De CegliTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.ORCID 0000-0002-8526-8692
Angela ZampelliTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Luca G Di GiovannantonioTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Edoardo NuscoTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Nick PlattDepartment of Pharmacology, University of Oxford, Oxford, UK.ORCID 0000-0002-1490-5447
Alessandro GuidaDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.ORCID 0000-0002-7160-750X
Margret Helga OgmundsdottirDepartment of Biochemistry and Molecular Biology, University of Iceland, Vatnsmyrarvegur 16, Reykjavik 101, Iceland.
Luisa LanfranconeDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.ORCID 0000-0002-4523-3815
Rushika M PereraDepartment of Anatomy and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
Roberto ZoncuDepartment of Molecular and Cellular Biology and Paul F. Glenn Center for Aging Research, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0003-1611-1891
Pier Giuseppe PelicciDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.ORCID 0000-0002-5076-2316
Carmine SettembreTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Andrea BallabioTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy. ballabio@tigem.it.ORCID 0000-0003-1381-4604
Telethon Institute Of Genetics And Medicine · ITEuropean Institute of Oncology · ITBaylor College of Medicine · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, Berkeley · USDulbecco Telethon Institute · ITUniversity of Iceland · ISUniversity of Milan · ITUniversity of Oxford · GB
Funding
PREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3MMODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASER01NS078072 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI BALLABIO, ANDREA · 2012 to 2020
$3.1MENGINEERING ORGANELLE FUNCTION TO REWIRE CANCER CELL METABOLISMDP2CA195761 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI ZONCU, ROBERTO · 2014 to 2014
$2.4MEuropean Research Council 250154European Research Council 341131NCI NIH HHS DP2 CA195761NIGMS NIH HHS T32 GM008568NINDS NIH HHS R01 NS078072
Abstract
The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that MiT/TFE transcription factors-master regulators of lysosomal and melanosomal biogenesis and autophagy-control mTORC1 lysosomal recruitment and activity by directly regulating the expression of RagD. In mice, this mechanism mediated adaptation to food availability after starvation and physical exercise and played an important role in cancer growth. Up-regulation of
Indexed as
Gene Expression Regulation, NeoplasticAnimalsCaloric RestrictionCell Line, TumorCell ProliferationCells, CulturedFeedback, PhysiologicalHEK293 CellsHeLa CellsHep G2 CellsHumansLiverMaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLMechanistic Target of Rapamycin Complex 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.